HSCT outcomes in children at Ramathibodi Hospital

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study reviews pediatric HSCT cases at Ramathibodi Hospital to identify factors that influence outcomes and to document post-transplant complications. It focuses on both related and unrelated donor HSCT, including settings with partially matched donors. Data collection covers patient preparation, conditioning regimens, perioperative care, and post-transplant follow-up. The goal is to inform pre-transplant planning and care to improve survival and quality of life. No experimental interventions are described beyond standard HSCT practice at the institution.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients with hematologic, malignant, or other diseases who underwent HSCT

Exclusion Criteria:

* Incomplete or loss of medical records

Where it's running

• Ramathibodi Hospital
  Ratchathewi, Bangkok, Thailand Recruiting

Study contacts

• Principal investigator: Usanarat Anurathapan, MD — Department of Pediatrics, Faculty of Medicine Ramathibodi Hospital, Mahidol University
• Study coordinator: Usanarat Anurathapan, MD
• Email: usanarat.anu@mahidol.ac.th
• Phone: 6622011803

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Reconstruction kinetics of γδ T cells after an unrelated cord blood transplant

  This study tests how γδ T cells recover after an unrelated cord blood transplant and whether recovery patterns relate to outcomes like graft-versus-host disease, relapse, and survival.

  Recruiting Anhui Provincial Hospital · Hefei, Anhui · NCT07782684

• JL19001 Injection Alone or with Standard Therapy in Advanced Solid Tumors or Relapsed/Refractory B-Cell NHL

  This phase 1 trial tests JL19001 by itself or with standard treatment to see if it is safe and tolerable in adults with advanced solid tumors or relapsed/refractory B-cell non-Hodgkin lymphoma.

  Recruiting Phase 1 Jecho Biopharmaceuticals Co., Ltd. · Beijing, Beijing Municipality · NCT07603479

• AOC 1044 in Duchenne Muscular Dystrophy with Exon 44 Skipping

  This study tests whether intravenous AOC 1044 helps boys with Duchenne muscular dystrophy caused by mutations amenable to exon 44 skipping.

  Recruiting at 20 sites Phase 3 Avidity Biosciences, Inc. · Westmead, New South Wales and 19 other locations · NCT07587242

• IASO207 Injection for relapsed or refractory B-cell cancers

  This early, single-center study tests IASO207 injections to see if they are safe and potentially beneficial for adults with relapsed or refractory B-cell malignancies who have not responded to standard therapies.

  Recruiting Early Phase 1 Peking University People's Hospital · Beijing · NCT07574346

• Clonal haematopoiesis assessment and long-term monitoring for prevention and care

  This project will follow people aged 55 and older who have clonal haematopoiesis or unexplained low blood counts to see how their blood changes over time and whether they develop heart disease or blood cancers.

  Recruiting Clinical Hub for Interventional Research (CHOIR) · Canberra, Australian Capital Territory · NCT07313059

• KLN-1010 gene therapy for relapsed or refractory multiple myeloma

  This Phase 1 trial will try KLN-1010, an in vivo CAR‑T gene therapy, to see if it is safe and can be given at a tolerable dose for people with relapsed or refractory multiple myeloma who have had at least three prior therapies.

  Recruiting at 11 sites Phase 1 Kelonia Therapeutics, Inc. · Duarte, California and 10 other locations · NCT07075185

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.